CytoSorbents restates 2023/2024 financials due to inventory and RSU errors

Cytosorbents Corp

Overstated inventory from clerical error; understated non-cash RSU expense due to using vesting-date fair value instead of grant-date.
Non-reliance applies to audited FY2023 10-K and unaudited Q1-Q3 2023 and Q1-Q3 2024 quarterly reports.
Restated financials will be included in the 2024 Annual Report on Form 10-K; prior reports should not be relied upon until then.
Audit committee and management discussed the errors with the independent registered public accounting firm.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.